These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 31824347)

  • 1. Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
    Bygrave AM; Kilonzo K; Kullmann DM; Bannerman DM; Kätzel D
    Front Psychiatry; 2019; 10():835. PubMed ID: 31824347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK-801 impairs working memory on the Trial-Unique Nonmatch-to-Location test in mice, but this is not exclusively mediated by NMDA receptors on PV+ interneurons or forebrain pyramidal cells.
    Sokolenko E; Nithianantharajah J; Jones NC
    Neuropharmacology; 2020 Jul; 171():108103. PubMed ID: 32330470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801.
    Bygrave AM; Masiulis S; Nicholson E; Berkemann M; Barkus C; Sprengel R; Harrison PJ; Kullmann DM; Bannerman DM; Kätzel D
    Transl Psychiatry; 2016 Apr; 6(4):e778. PubMed ID: 27070406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABAergic interneuron origin of schizophrenia pathophysiology.
    Nakazawa K; Zsiros V; Jiang Z; Nakao K; Kolata S; Zhang S; Belforte JE
    Neuropharmacology; 2012 Mar; 62(3):1574-83. PubMed ID: 21277876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The origin of NMDA receptor hypofunction in schizophrenia.
    Nakazawa K; Sapkota K
    Pharmacol Ther; 2020 Jan; 205():107426. PubMed ID: 31629007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers.
    Benneyworth MA; Roseman AS; Basu AC; Coyle JT
    Neurosci Lett; 2011 Jan; 488(3):267-71. PubMed ID: 21094213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Garzón J
    Front Pharmacol; 2014 Jan; 4():169. PubMed ID: 24427139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.
    Jeevakumar V; Kroener S
    Cereb Cortex; 2016 Mar; 26(3):1117-29. PubMed ID: 25477370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.
    Gonzalez-Burgos G; Lewis DA
    Schizophr Bull; 2012 Sep; 38(5):950-7. PubMed ID: 22355184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction.
    Phensy A; Lindquist KL; Lindquist KA; Bairuty D; Gauba E; Guo L; Tian J; Du H; Kroener S
    J Neurosci; 2020 Aug; 40(32):6121-6132. PubMed ID: 32605939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia.
    Jadi MP; Behrens MM; Sejnowski TJ
    Biol Psychiatry; 2016 May; 79(9):716-726. PubMed ID: 26281716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased excitation-inhibition balance and loss of GABAergic synapses in the serine racemase knockout model of NMDA receptor hypofunction.
    Jami SA; Cameron S; Wong JM; Daly ER; McAllister AK; Gray JA
    J Neurophysiol; 2021 Jul; 126(1):11-27. PubMed ID: 34038186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.
    Snyder MA; Gao WJ
    Schizophr Res; 2020 Mar; 217():60-70. PubMed ID: 30979669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interneuron NMDA Receptor Ablation Induces Hippocampus-Prefrontal Cortex Functional Hypoconnectivity after Adolescence in a Mouse Model of Schizophrenia.
    Alvarez RJ; Pafundo DE; Zold CL; Belforte JE
    J Neurosci; 2020 Apr; 40(16):3304-3317. PubMed ID: 32205341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex.
    Xi D; Zhang W; Wang HX; Stradtman GG; Gao WJ
    Int J Neuropsychopharmacol; 2009 Nov; 12(10):1395-408. PubMed ID: 19435549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-matching-to-position working memory in mice relies on NMDA-receptors in prefrontal pyramidal cells.
    Kilonzo K; van der Veen B; Teutsch J; Schulz S; Kapanaiah SKT; Liss B; Kätzel D
    Sci Rep; 2021 Apr; 11(1):8788. PubMed ID: 33888809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia.
    Nakazawa K; Jeevakumar V; Nakao K
    NPJ Schizophr; 2017; 3():7. PubMed ID: 28560253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reviewing the ketamine model for schizophrenia.
    Frohlich J; Van Horn JD
    J Psychopharmacol; 2014 Apr; 28(4):287-302. PubMed ID: 24257811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia.
    Sapkota K; Mao Z; Synowicki P; Lieber D; Liu M; Ikezu T; Gautam V; Monaghan DT
    J Pharmacol Exp Ther; 2016 Mar; 356(3):702-11. PubMed ID: 26675679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.